Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Memorial Sloan Kettering Cancer Center Identifier:
First received: December 10, 1999
Last updated: March 6, 2013
Last verified: March 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2003
  Primary Completion Date: October 2003 (Final data collection date for primary outcome measure)